INTRODUCTION

There are two modalities of brain stimulation: non-invasive and invasive, and along the time, several techniques have been developed within both categories (Box 1). The non-invasive stimulation is done by two techniques: transcranial magnetic stimulation (TMS), which was introduced in 1985, and transcranial electrical stimulation (tES). The transcranial direct current stimulation (tDCS) is the most modern and most used form of tES. These non-invasive techniques are applied directly through electrodes or magnetic fields on the scalp of the patient to produce electrical currents for the stimulation of brain cells. However, invasive stimulation, such as deep brain stimulation (DBS), involves passing electric current into the subcortical area through surgically implanted electrodes deeper in the brain. Unlike invasive, non-invasive methods do not require anesthesia and surgical operation, and therefore, these are preferred over invasive methods. Both non-invasive techniques, rTMS and tDCS, have been used in clinical settings, are already regulated for clinical use in many countries and, currently, are approved by the Food and Drug
Administration (FDA). On the other hand, invasive technique, DBS, is also an FDA-approved treatment and, in the late 1980s, it began to emerge as a life-changing therapy for patients with involuntary movement disorders.

2 | NON-INVASIVE BRAIN STIMULATION

2.1 | Transcranial magnetic stimulation

TMS is a neuromodulation technique that uses large transient magnetic fields to induce focal electrical fields in a specific brain area, and the availability of sophisticated equipment has made it possible to employ repetitive TMS (rTMS). The effects of rTMS vary depending on the shape of the coil (figure of eight, H coil, double cone coil),2 pacing pattern (high frequency, low frequency, theta-burst), and stimulation site. In fact, TMS is considered as a tool with great therapeutic potential because it is safe and the risk of severe negative side effects upon application is very low.

2.1.1 | Mechanism of action

TMS induces short pulses of intracranial electrical current and is applied in several ways: as single pulse, as paired pulse to the same or different brain areas, or as rTMS. Single-pulse stimulus depolarizes neurons3; however, rTMS can induce changes in excitability of the cerebral cortex, locally as well as in neurons at areas far from the stimulation site, along functional anatomical connections.3,4 Although underlying mechanisms of the therapeutic outcomes of rTMS application have not been fully elucidated, rTMS can induce changes in cerebral blood flow,5 oxygen consumption, cortical activity,6 and release of neurotransmitters.7,8 Therefore, it has been argued that these functional changes might be associated with positive clinical results.
2.1.2 | TMS application to alleviate the symptoms of neurological disorders

For effective rTMS application, adjustments in both spatial and temporal parameters are essential. In literature, for the determination of spatial location of a target in brain, 52% of the studies have used magnetic resonance imaging, 27% scalp measurement, 15% functional magnetic resonance imaging, and 6% hotspot targeting.9 Similarly, temporal parameters, which include stimulation frequency, number of pulses per trial, and interval duration between each stimulus, are also diverse. For stimulation frequency, few studies have used low-frequency stimulation of 1 Hz and most studies have applied a high-frequency stimulation ranging from 5 Hz (in 14%), 10–19 Hz (in 67%), to more than 20 Hz (in 20%). The stimulus interval time varied from 300 ms to 37,400 ms, and the number of pulses administered in each trial was <10; however, some studies applied more than 20 pulses. Additionally, combining rTMS with concurrent behavioral interventions in some neurological disorders has turned out to be more effective.10 Therapeutic benefits of rTMS are summarized in Table 1.

Parkinson’s disease

A progressive degeneration of dopaminergic neurons in the basal ganglia leads to severe impairment in motor functions of patients with Parkinson’s disease (PD). The application of rTMS by several clinical groups found that PD patients improved motor functions upon application of high-frequency (10 Hz) rTMS in M1 area of motor cortex and most patients showed improvements in bradykinesia.11–15 The motor improvements in PD patients were associated with changes in neuronal activity.16 Furthermore, a meta-analysis of 23 studies with total of 646 patients found that the application of rTMS to the motor cortex area of brain produces a significant long-term improvement in motor functions.14

Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disease that causes cognitive deficits and is the most common form of dementia. The application of rTMS in AD patients has been shown to improve motor17,18 and cognitive functions.19,20 The cognitive improvement was observed immediately and one month after the treatment but not after 6 months.21,22 Furthermore, the application of high-frequency (10 Hz) TMS significantly improved cognitive performance in AD patients with mild deterioration,23,24 and similarly, meta-analysis studies found that rTMS is effective in treating cognitive dysfunctions in AD patients.25,26

Vascular dementia

Vascular dementia is the second most common form of dementia after AD, and it accounts for at least 20% of dementia cases. A study in rats with vascular dementia showed that application of TMS was able to improve spatial learning and memory,27 protect pyramidal cells from apoptosis, and promote synaptic plasticity in the CA1 area of the hippocampus.28,29 However, the studies in humans are scarce. Nevertheless, a randomized controlled pilot study in 7 patients with vascular disease and mild cognitive deficits without vascular dementia showed that one session of high-frequency rTMS applied to the left DLPFC improved executive functioning, whereas no effects on any other cognitive functions were observed.30 Another study in patients with vascular disease and vascular cognitive impairments but without dementia found that the stimulation of left DLPFC and not left M1 area with 4 sessions of rTMS significantly improved the cognitive ability.31

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder (ADHD) is primarily associated with deficits in attention and executive functions. A pilot study in 9 adolescents and young adults with ADHD found significant improvement after the treatment with high-frequency (10 Hz) rTMS.32 Another pilot study in 43 adult ADHD patients showed that the application of high-frequency (18 Hz) rTMS for 3 weeks caused significant improvement in ADHD symptoms.33 In contrast, a study in adult ADHD patients reported no effect after application of deep TMS (dTMS).34 The effect of standard rTMS is more focal and reaches a depth of 0.7 cm, while the effect of dTMS is broader and reaches a significant depth of 3.2 cm. Therefore, it seems that a focal treatment with rTMS is more effective in the treatment of ADHD.

Dyslexia

Dyslexia affects at least 5% of school-aged children and is characterized by difficulty in learning to read and spelling of written texts. Most dyslexics have difficulties in relating alphabet letters to the sounds they symbolize. So far, there is no study with larger number of dyslexia patients. In a study with 10 dyslexics, treatment with high-frequency (5 Hz) rTMS to areas that are not very active in dyslexics during reading, such as the left superior temporal gyrus and the left inferior parietal lobe, improved both precision and reading speed of the dyslexic adults.35

Autism spectrum disorder

Autism spectrum disorder (ASD) is a developmental disorder and is characterized by the difficulty in social interaction and emotional recognition, repetitive behaviors, and lack of interest. The prevalence of ASD is estimated at 1 every 110 births with a higher incidence in children.36–38 In a study, application of low-frequency (1 Hz) rTMS on DLPFC area of autistic patients caused significant improvements in the process of goal recognition, reduction of motor errors to specific stimuli, and reduction of repetitive and stereotactic behaviors.39 Another study showed that autistic youths as well as adults improved their executive functions after the application of high-frequency (20 Hz) rTMS on the DLPFC.40 In the same line, a review of 24 studies with 317 ASD patients and a meta-analysis of 23 studies with 339 ASD patients found that the application of rTMS improved the ASD symptoms in patients.41,42
| Disorder                      | Participant size | Stimulation site | Stimulus frequency | Outcome of treatment                                                                 | Effect size or SMD and p-value | References and comment |
|-------------------------------|------------------|-----------------|--------------------|--------------------------------------------------------------------------------------|-------------------------------|------------------------|
| Parkinson’s disease          | 646              | M1              | High frequency (10–50 Hz) | Long-term motor function improvement                                                 | 0.97 (p < 0.01)               | Yang et al., 2018 (Meta-analysis of 23 studies) |
| Alzheimer’s disease          | 293              | DLPFC           | Low frequency (1 Hz)  | Improvement in memory functions                                                      | 1.53 (p < 0.005)              | Chou et al., 2019 (Meta-analysis of 13 studies) |
|                              | 94               | DLPFC           | High frequency (>1 Hz) | Improvement in cognitive functions                                                   | 1.00 (p = 0.0008)             | Liao et al., 2015 (Meta-analysis of 7 studies) |
| Attention deficit hyperactivity disorder | 43           | PFC             | High frequency (18 Hz) | Improvement in ADHD symptoms                                                         | 0.96 (p = 0.0009)             | Alyagon et al., 2020 (Clinical trial) |
|                              | 7                | PFC             | High frequency (10 Hz) | Improvement in ADHD symptoms                                                         | 0.48 (p < 0.05)               | Weaver et al., 2012 (Pilot study) |
| Dyslexia                     | 10               | IPL and STG     | High frequency (5 Hz)  | Improvement in reading performance                                                   | 0.54 (p < 0.001)              | Costanzo et al., 2013 (Pilot study) |
| Autism spectrum disorder     | 317              | DLPFC (16 studies) | Low to high frequency (0.5–50 Hz) | Significant improvement in repetitive behavior, sociability, and cognitive and executive functions | ND                           | Khaleghi et al., 2020 (Review of 24 studies) |
|                              |                  | PFC (3 studies) |                     |                                                                                      |                               |                        |
|                              |                  | SMA (3 studies) |                     |                                                                                      |                               |                        |
|                              |                  | PMC (1 study)   |                     |                                                                                      |                               |                        |
|                              |                  | Multiple sites (1 study) |                   |                                                                                      |                               |                        |
|                              | 339              | DLPFC (15 studies) | Low to high frequency (>0.5) | Improvement in repetitive and stereotyped behaviors, social behavior, and executive functions | 0.29–0.53 (p < 0.008)         | Barahona-Correa et al., 2018 (Meta-analysis of 23 studies) |
|                              |                  | PFC (3 studies) |                     |                                                                                      |                               |                        |
|                              |                  | PMC (3 studies) |                     |                                                                                      |                               |                        |
|                              |                  | Multiple sites (2 study) |                   |                                                                                      |                               |                        |
| Chronic pain                 | 682              | M1              | High frequency (5–20 Hz) | Significant reduction in pain intensity (up to 32%)                                 | ND                           | Gatzinsky et al., 2020 (Systematic review of 24 studies) |
|                              | 250              | M1              | High frequency (5–20 Hz) | Significant pain relief and long-lasting analgesic effect                            | ND                           | Hamid et al., 2019 (Systematic review of 7 clinical trials) |
|                              | 727              | M1              | High frequency (5–20 Hz) | Significant pain relief (>30%)                                                       | ND                           | Galhardoni et al., 2015 (Review of 27 clinical trials) |

Abbreviations: DLPFC, dorsolateral prefrontal cortex; IPL, inferior parietal lobe; M1, primary motor cortex; ND, not determined; PFC, prefrontal cortex; PMC, premotor cortex; SMA, supplementary motor area; SMD, standardized mean difference; STG, superior temporal gyrus.
**Down syndrome**

Down syndrome is a genetic disorder; however, patients with Down syndrome show various neurological symptoms, such as neuromotor abnormalities, reduced learning capacity, cognitive and language alterations, and hampered reading skills. The first study with TMS on the motor cortex showed that young people with Down syndrome have normal cortical excitability, but altered cortical synaptic plasticity. So far, there is no study of TMS application to improve the language and cognitive alterations in Down syndrome.

**Chronic pain**

Chronic pain is a disorder associated with various pathologies and is thought to develop from CNS nerves damage. It has been shown that a single stimulation with high-frequency TMS produced small (12%) but short-term reduction in pain intensity, which was not considered as clinically meaningful. However, a systematic review of 12 randomized clinical trials involving 350 patients with focal or generalized chronic pain found that low-frequency rTMS stimulation produced no effect, whereas high-frequency stimulation induced long-lasting analgesic effect and meaningful relief from chronic pain.

**2.2 Transcranial direct current stimulation**

TDCS is the most used form of electrical stimulation. In comparison with rTMS, TDCS is not as powerful and generates weak stimulus; however, it is relatively easy to use and transport, lot less expensive, and it has low incidence of side effects. The effect of TDCS varies according to the type of current (direct, alternating, pulsed, random noise), polarity (anodal or cathodal), current intensity, and stimulation site.

**2.2.1 Mechanism of action**

TDCS modulates neural activity by delivering low-amplitude electrical current through electrodes and therefore causes a change in the cortical excitability. An anodal TDCS stimulation enhances excitatory synaptic transmission by stimulating glutamate transmission and suppressing gamma-aminobutyric acid (GABA) transmission and that the change in the balance between glutamate and GABA activities leads to modification in functional connectivity between brain regions. The effect of anodal TDCS stimulation also extends to other brain areas through decrease/increase in axonal release of monoamine transmitters, such as dopamine. In addition, an anodal TDCS stimulation has been shown to cause induction in long-term potentiation (LTP), increase in cAMP accumulation and mRNA expression, which are kinds of biological activities that facilitate the processing of cognitive functions.

**2.2.2 tDCS application to alleviate the symptoms of neurological disorders**

Therapeutic benefits of TDCS are summarized in Table 2.

**Alzheimer’s disease**

Studies have shown that TDCS can stabilize verbal memory in patients with AD dementia and enhance the listening comprehension. The stimulation of left DLPFC with TDCS for 5 days produced significant improvement in immediate and delayed recall performance of a picture memory and that this improvement persisted for one month. In addition, a meta-analysis of 7 studies with a total of 146 mild-to-moderate AD patients showed that TDCS stimulation significantly improved the cognitive functions. Similarly, other meta-analysis studies also found an improvement in cognitive functions of AD patients after TDCS stimulation.

**Parkinson’s disease**

Several studies have shown that TDCS is beneficial in improving movement disorders in PD patients. A systematic review of 29 studies involving single TDCS session with 256 PD patients and repeated TDCS sessions with 294 PD patients found significant improvement in motor symptoms, including mobility, balance, gait velocity, and falling. Similarly, meta-analysis of 18 studies in 325 PD patients and of 9 studies in 152 PD patients revealed that TDCS stimulation significantly improved PD symptoms, including walking performance, gait, and bradykinesia.

**Autism spectrum disorder**

An application of TDCS in children and adolescents with ASD has been shown to increase brain functional connectivity and cause improvement in behavioral and cognitive symptoms. Both cathodal and anodal TDCS stimulation are adequate in successfully reducing ASD symptoms even in medication-resistant patients.

**Down syndrome**

A study with 22 Down syndrome children of ages between 6 and 12 years showed that the application of 10 sessions of anodal TDCS on the primary motor cortex during the upper limb motor training enhanced motor control for a reach movement. Similarly, a case report found that anodal TDCS combined with upper limb motor training led to improvement in duration and velocity of movement. Even though these results are encouraging, there is lack of comprehensive studies on the effects of TDCS application in patients with Down syndrome.

**Dyslexia**

Studies in dyslexic children and adolescents have shown that a treatment with TDCS causes improvement in reading skills and reduction in word reading errors and wordless reading time gap. A study in 10 dyslexic children further demonstrated that the application of anodal TDCS improved text accuracy, word recognition speed, motion perception, and attentional focusing. In addition, TDCS
| Disorder                     | Participant size | Stimulation site                                      | Stimulus current density (mA/cm²) | Outcome of treatment                                      | Effect size or SMD and \( p \)-value | References and comment               |
|------------------------------|------------------|------------------------------------------------------|-----------------------------------|----------------------------------------------------------|-------------------------------------|-------------------------------------|
| Alzheimer’s disease          | 146              | DLPFC (3 studies) Temporal cortex (3 studies) Temporoparietal areas (1 study) | 0.06–0.08 (single session)        | Improvement in cognitive performance                      | 0.84 (\( p = 0.002 \))             | Cai et al., 2019 (Meta-analysis of 7 studies) |
|                              | 93               | DLPFC (3 studies) Temporoparietal areas (1 study) Temporal cortex (1 study) | 0.06–0.08                         | Improvement in cognitive functions                        | 1.35 (\( p < 0.001 \))             | Hsu et al., 2015 (Meta-analysis of 5 studies) |
| Parkinson’s disease          | 325              | M1 (9 studies) DLPFC (4 studies) PFC (1 study) Multiple sites (4 studies) | 0.028–0.13                        | Improvement in locomotion                                | 0.36 (\( p = 0.001 \))             | Lee et al., 2019 (Meta-analysis of 18 studies) |
|                              | 152              | M1 (4 studies) PFC (2 studies) Multiple sites (3 studies) | 0.02–0.06                         | Improvement in gait                                       | 0.61 (\( p = 0.005 \))             | Goodwill et al., 2017 (Meta-analysis of 9 studies) |
| Attention deficit hyperactivity disorder | 241              | DLPFC (10 studies) IFG (1 study)                      | 0.02–0.08                        | Significant improvement in attention, inhibitory control and working memory | ND                                  | Cosmo et al., 2020 (Systematic review of 11 studies) |
|                              | 169              | DLPFC                                                 | 0.028–0.08                        | Improvement in inhibitory control and working memory     | 2.42–2.76 (\( p < 0.015 \))         | Salehinejad et al., 2019 (Meta-analysis of 9 studies) |
| Dyslexia                     | 10               | Temporoparietal areas                                 | 0.04                             | Improvement in text accuracy, word recognition speed, perception, and attentional focusing | 2.50 (\( p = 0.01 \))              | Lazzaro et al., 2021 (Pilot study)     |
|                              | 63               | Temporoparietal areas                                 | 0.04                             | Significant improvement in reading ability                | ND                                  | Finisguerra et al., 2019 (Systematic review of 3 studies) |
| Disorder                  | Participant size | Stimulation site          | Stimulus current density (mA/cm²) | Outcome of treatment                                                                 | Effect size or SMD and p-value | References and comment |
|--------------------------|------------------|---------------------------|----------------------------------|--------------------------------------------------------------------------------------|-------------------------------|------------------------|
| Autism spectrum disorder | 84               | DLPFC (6 studies)         | 0.02–0.08                       | Significant improvement in repetitive behavior, sociability, and cognitive and executive functions | ND                            | Khaleghi et al., 2020†2 | (Systematic review of 8 studies) |
|                          | 69               | DLPFC                     | 0.028–0.17                      | Reduction in ASD symptoms                                                              | ND                            | Osorio et al., 2019†4   | (Systematic review of 5 studies) |
|                          | 266              | DLPFC (10 studies)        | 0.028–0.08                      | Improvement in socialization, repetitive behavior, and sensory and cognitive awareness | 0.97 (p < 0.001)              | García-González et al., 2021†2 | (Meta-analysis and review of 19 studies) |
| Epilepsy                 | 328              | Temporal lobe (2 studies) | 0.028–0.17                      | Significantly reduced seizures frequency                                              | ND                            | Sudbrack-Oliveira et al., 2019†0 | (Systematic review of 27 studies) |
|                          | 128              | Temporal lobe (2 studies) | 0.028–0.08                      | Significantly reduced seizures frequency                                              | ND                            | Regner et al., 2018†8   | (Systematic review of 12 studies) |
| Cerebral palsy           | 128              | M1                        | 0.028–0.04                      | Significant improvement in gait, mobility, and balance                                | ND                            | Fleming et al., 2018†05 | (Review of 10 studies) |
|                          | 373              | M1                        | 0.028–0.04                      | Improvement in velocity, stride length, and cadence                                  | 3.75–4.48 (p < 0.0005)        | Saleem et al., 2019†07 | (Review and meta-analysis of 17 studies) |
|                          | 178              | M1 (8 studies) Cerebellum (1 study) | 0.028–0.04                      | Improvement in gait velocity and step length                                           | 0.23 (p < 0.01)               | Hamilton et al., 2019†06 | (Review and meta-analysis of 9 studies) |
| Chronic pain             | 747              | M1                        | 0.025–0.083                     | Reduction in pain intensity and improvement in quality of life                       | 0.43–0.66 (p < 0.05)          | O’Connell et al., 2018†47 | (Review and meta-analysis of 27 studies) |

Abbreviations: DLPFC, dorsolateral prefrontal cortex; IFG, inferior frontal gyrus; M1, primary motor cortex; ND, not determined; PFC, prefrontal cortex; SMD, standardized mean difference.
stimulation combined with training for reading in children and adolescents with dyslexia produced long-lasting improvement in reading. Application of tDCS also improved reading speed and fluency in dyslexic adults.

Attention deficit hyperactivity disorder
Several meta-analysis and other studies in ADHD patients have shown that the tDCS treatment increases brain connectivity and improves behavior, attention, working memory, inhibitory control, and cognitive flexibility. In addition, a study in 37 ADHD patients showed that tDCS causes an improvement in impulsivity symptoms.

Epilepsy
Studies in children and adults with focal as well as refractory focal epilepsy have shown that a stimulation with cathodal tDCS decreases epileptiform discharges. Similarly, several meta-analysis and systematic reviews found that cathodal tDCS application in epileptic patients with either focal epilepsy or refractory focal epilepsy successfully restrained epileptiform activity and reduced seizure frequency.

Cerebral palsy
Cerebral palsy is a permanent movement disorder that is caused by abnormal motor development or damage to the parts of brain that control movement, balance, and posture. Recent studies in children and adolescents with cerebral palsy have shown that tDCS stimulation combined with physiotherapeutic training improves body roll speed, balance, mobility, and walking distance and decreases spasticity and gait. These studies showed that single tDCS session caused improvement for a short period; however, tDCS treatment sessions ranging from several weeks to few months produced more sustained effect. A treatment with tDCS alone also improved mobility, gait, and balance in pediatric cerebral palsy patients.

Chronic pain
Studies have shown that a treatment with tDCS on the M1 area causes long-lasting relief in medication-resistant patients with chronic pain syndrome such as trigeminal neuralgia, post-stroke pain, back pain, and fibromyalgia. The efficacy of tDCS in alleviating pain has also been shown in patients with multiple sclerosis joint pain, neuropathic pain, spinal cord injury, fibromyalgia, chronic migraine, foot pain, and intra-abdominal pain. A meta-analysis studies further found that a treatment with tDCS reduces chronic pain intensity.

3 | INVASIVE BRAIN STIMULATION

3.1 | Deep brain stimulation

DBS treatment implies passing electric current into the subcortical nuclei of the brain through surgically implanted electrodes. In contrast to rTMS and tDCS, DBS treatment in some of the brain nuclei has been shown to produce severe side effects.

3.1.1 | Mechanism of action

Although how DBS produces improvements remains not well understood, it has been shown that DBS treatment changes brain activity in a controlled way. The effects of DBS tend to cause excitation in neighboring axons, improvement in microvascular integrity, increase in local cerebral blood flow, and stimulation in astrocytes to release calcium, which can further lead to the release of glutamate and adenosine. Nevertheless, from a neurophysiological point of view, the “disruption hypothesis” appears to be increasingly accepted. According to this hypothesis, DBS dissociates the input and output signals and causes a disruption in the anomalous flow of information.

3.1.2 | DBS application to alleviate the symptoms of neurological disorders

Therapeutic benefits of DBS are summarized in Table 3.

Alzheimer’s disease
A case study found that the fornical DBS in a patient with severe AD symptoms improved the activities of daily living but had no effect on cognition, and a phase II and two-year follow-up study in 42 patients with more than 65 years of age and mild AD showed that the application of DBS in the fornix improved memory. Similarly, a review of 16 studies with 174 AD patients and another review of 9 studies with 45 AD patients found that a stimulation with DBS in fornix caused improvement in memory and slowed down the cognitive decline. In addition, application of DBS in entorhinal cortex and nucleus basalis of Meynert has also been shown to be beneficial for improving memory in AD patients.

Parkinson’s disease
DBS is effectively used in the management of motor functions in PD patients and the most common target areas have been globus pallidus pars interna (GPI) and subthalamic nucleus (STN). Several meta-analysis studies found that the application of DBS improved motor functions as well as daily living activities. In addition, a study of combined effect of DBS in STN and levodopa medication showed that the DBS stimulation and levodopa medication independently improved motor symptoms to a similar extent in PD patients; however, the combined effect was greater than either one of the treatments.

Essential tremor
DBS is considered as an effective and safe therapy for essential tremor. Several meta-analysis studies in essential tremor patients found significant improvement after DBS treatment.

Autism spectrum disorder
In a case report, application of DBS in basolateral amygdala caused improvement in the core symptoms of ASD and the related self-injurious behavior in a patient of 13 years of age. Similarly, in
| Disorder                  | Participant size | Stimulation site                      | Stimulus (Hz) | Outcome of treatment                                      | Effect size, SMD, or overall effect and p-value | References and comment |
|--------------------------|------------------|---------------------------------------|---------------|----------------------------------------------------------|------------------------------------------------|------------------------|
| Alzheimer’s disease      | 132              | Fornix (8 studies)                    | 20–130        | Improvement in memory and reduction in cognitive decline | ND                                              | Luo et al., 2021124 (Review of 16 studies) |
|                          |                  | NBM (7 studies)                       |               |                                                          |                                                 |                        |
|                          |                  | VC / VS (1 study)                     |               |                                                          |                                                 |                        |
|                          |                  | STN (8 studies)                       | 130–167       | Improvement in motor function and activities of daily living | 2.40–6.36 ($p < 0.02$) | Bratos et al., 2018126 (Meta-analysis of 8 studies) |
| Parkinson’s disease      | 1189             | STN (5 studies)                       | 130–167       | Improvement in motor function and activities of daily living | 2.40–6.36 ($p < 0.02$) | Bratos et al., 2018126 (Meta-analysis of 8 studies) |
|                          |                  | STN/GPI (2 studies)                   |               |                                                          |                                                 |                        |
|                          |                  | CZI (1 study)                         |               |                                                          |                                                 |                        |
|                          |                  | STN (1 study)                         | 25–185        | Improvement in motor functions                           | 3.43 ($p < 0.01$)                                 | Mao et al., 2019127 (Meta-analysis of 16 studies) |
|                          |                  | GPI/STN (4 studies)                   |               |                                                          |                                                 |                        |
|                          |                  | GPI (2 studies)                       |               |                                                          |                                                 |                        |
|                          |                  | PPN (2 studies)                       |               |                                                          |                                                 |                        |
|                          |                  | VIM (2 studies)                       |               |                                                          |                                                 |                        |
| Essential tremor         | 1202             | VIM                                   | 50–200        | Improvement in tremor severity (>60%) and quality of life (>56%) | ND                                              | Giordano et al., 2020132 (Systematic review of 38 studies) |
|                          |                  |                                       |               |                                                          |                                                 |                        |
|                          |                  |                                       |               | Significant improvement in essential tremor              | ND                                              | Flora et al., 2010130 (Systematic review of 17 studies) |
| Epilepsy                 | 328              | ANT (20 studies)                      | 60–185        | Significant reduction in seizure frequency (>56%)        | ND                                              | Zhou et al., 2018139 (Review of 37 studies) |
|                          |                  | CMT (7 studies)                       |               |                                                          |                                                 |                        |
|                          |                  | Hippocampus (10 studies)              |               |                                                          |                                                 |                        |
|                          |                  | ANT (1 study)                         | 10–190        | Reduction in seizure frequency                           | 2.26–9.27 ($p < 0.02$) | Sprengers et al., 2017137 (Meta-analysis of 7 clinical trials) |
|                          |                  | CMT (2 studies)                       |               |                                                          |                                                 |                        |
|                          |                  | Hippocampus (4 studies)               |               |                                                          |                                                 |                        |
| Chronic pain             | 304              | PAG/PVG and/or VPL/VPM                | 5–162         | Significant reduction in pain intensity (upto 60%)       | ND                                              | Galafassi et al., 2021141 (Systematic review of 11 studies) |
|                          |                  |                                       |               |                                                          |                                                 |                        |
|                          |                  |                                       |               | Significant reduction in pain intensity (upto 60%)       | ND                                              | Frizon et al., 2020140 (Systematic review of 22 studies) |
|                          |                  |                                       |               |                                                          |                                                 |                        |
| Tourette syndrome        | 162              | GPI (11 studies)                      | 20–185        | Significant reduction in tic severity (>57%)             | 1.96 ($p < 0.001$)                               | Coulombe et al., 2018145 (Meta-analysis of 21 studies) |
|                          |                  | Thalamus (4 study)                    |               |                                                          |                                                 |                        |
|                          |                  | GPI/Thalamus (6 studies)              |               |                                                          |                                                 |                        |
|                          |                  |                                       |               | Significant reduction in tic severity (>52%)             | 0.96 ($p = 0.002$)                               | Baldermann et al., 2016147 (Meta-analysis of 48 studies) |
|                          |                  |                                       |               |                                                          |                                                 |                        |
|                          |                  |                                       |               | Significant reduction in tic severity (>52%)             | 0.96 ($p = 0.002$)                               | Baldermann et al., 2016147 (Meta-analysis of 48 studies) |
|                          |                  |                                       |               |                                                          |                                                 |                        |

Abbreviations: ACC, anterior cingulate cortex; ALIC/NAC, anterior limb of the internal capsule/nucleus accumbens; ANT, anterior nucleus of thalamus; CMT, centromedian nucleus of thalamus; CZI, caudal zona incerta; GPI, globus pallidus internus; NBM, nucleus basalis de Meynert; ND, not determined; PAG/PVG, periaqueductal/periventricular gray matter region; PLIC, posterior limb of internal capsule; PPN, pedunculopontine nucleus; SMD, standardized mean difference; STN, subthalamic nucleus; VC/VS, ventral capsule/ventral striatum; VIM, thalamic ventral intermediate nucleus; VPL/VPM, ventral posterior lateral/posterior medial thalamus; VS/ALIC, ventral striatum/anterior limb of the internal capsule.
another case report, a 14-year-old boy with ASD and self-injurious behavior treated with DBS in nucleus accumbens showed significant improvement as well. Nevertheless, there is lack of comprehensive study in a larger number of patients to demonstrate the efficacy of DBS in ASD.

Epilepsy

Four patients with partial and generalized epileptic seizures who received DBS treatment in thalamus showed 49% reduction in seizures over a period of 44 months, and one of the patients did not suffer seizures for 15 months. A multicenter, double-blind, randomized study in 110 adults with refractory partial seizures showed decrease in seizures for 2 years; however, long-term follow-up of the same study further confirmed the efficacy of this therapy even 5 years after the treatment. In addition, several reviews and meta-analysis studies have shown that DBS treatment induces significant reduction in seizures frequency in epileptic as well as refractory epileptic patients.

Chronic pain

DBS has been shown to be effective in reducing chronic pain up to 60% in patients. A study in 16 patients with chronic pain showed that DBS-mediated stimulation of thalamus produced considerable reduction in pain and this effect persisted 36 months after the treatment. Similar to the treatment in thalamus, a study of DBS in anterior cingulate cortex also found significant improvement in pain, and the effect of the treatment lasted for an average of 18 months and 39 months after the treatment.

Tourette syndrome

Tourette syndrome is a neurodevelopmental disorder characterized by the appearance of involuntary repetitive motor and vocal tics. High percentage of patients also present other brain disorders, such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). A meta-analysis study found that DBS-mediated stimulation of both the GPi and the thalamic nucleus improved tics and decreased OCD in patients, and a review of 48 studies in 120 patients with Tourette syndrome found substantial improvement in the severity of tics. Similarly, other reviews and meta-analysis studies identified that the stimulation of thalamus, globus pallidus, or nucleus accumbens produced overall improvement in the symptoms of Tourette syndrome.

4 | CONCLUDING REMARKS

The success of brain stimulation treatment lies in the availability of an effective tool and the most desirable device would be the one which not only can penetrate deep into the brain and focally modulate a specific region and only that region but also is cheap, portable, and painless, and can be applied in awake, alert humans. However, currently available devices fall short of such expectations. Considering that brain stimulation technologies continue to evolve and advancing rapidly, more versatile tools are expected to develop in near future. Nonetheless, within the currently available non-invasive devices, tDCS involves passing relatively weak direct current in the brain and is inexpensive and relatively safe. While TMS is more expensive and might occasionally cause a seizure (<1%), it is powerful. In contrast, tDCS cannot cause a seizure and is weak. DBS, which is an invasive technique, is often used as a last resort for treating patients who have shown no relief after other viable therapies, and compared to tDCS and TMS, DBS produces serious side effects. For example, there is high rate of suicide in patients treated with DBS, particularly with stimulation in STN and GPi areas of brain. Within TMS, tDCS, and DBS techniques of brain stimulation, TMS is the most used in clinical applications. Currently, more than 2000 clinical trials are registered in clinicaltrials.gov for TMS. This number is in fact almost twice of clinical trials registered for either tDCS or DBS. In addition, TMS also supersedes in the number of publications recorded in PubMed. Considering that TMS technology continues to evolve as we have seen with the development of new broad and deep TMS coils, it is likely that TMS may adopt in future and become the most desirable and sophisticated device.

ACKNOWLEDGMENTS

J. A. Camacho-Conde received Postdoctoral Fellowship from Intramural Research Funds of Universidad de Malaga. M. Carretero-Rey is Research Fellow of project CTS-586 from Junta de Andalucia.

CONFLICT OF INTEREST

Authors declare no conflict of interest.

ORCID

Jose Antonio Camacho-Conde https://orcid.org/0000-0002-6912-8462
Zafar U. Khan https://orcid.org/0000-0003-0742-399X

REFERENCES

1. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;1(8437):1106-1107.
2. Deng ZD, Lisanby SH, Peterchev AV. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimul. 2013;6(1):1-13.
3. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol. 2003;2(3):145-156.
4. Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann Phys Rehabil Med. 2015;58(4):208-213.
5. Richieri R, Boyer L, Padovani R, et al. Equivalent brain SPECT perfusion changes underlying therapeutic efficiency in pharmacoresistant depression using either high-frequency left or low-frequency right prefrontal iTMS. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):364-370.
6. Yamanaka K, Tomioka H, Kawasaki S, et al. Effect of parietal transcranial magnetic stimulation on spatial working memory in healthy elderly persons - comparison of near infrared spectroscopy for young and elderly. PLoS One. 2014;9(7):e102306.
7. Lenz M, Galanis C, Muller-Dahlhaus F, et al. Repetitive magnetic stimulation induces plasticity of inhibitory synapses. Nat Commun. 2016;7:10020.
8. Su L, Cai Y, Xu Y, Dutt A, Shi S, Bramon E. Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. *BMJ Psychiatry*. 2014;14:321.

9. Beynel L, Appelbaum LG, Luber B, et al. Effects of online repetitive transcranial magnetic stimulation (rTMS) on cognitive processing: A meta-analysis and recommendations for future studies. *Neurosci Biobehav Rev*. 2019;107:47-58.

10. Sathappan AV, Luber BM, Lisanby SH. The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;89:347-360.

11. Khedr EM, Rothwell JC, Shawky OA, Ahmed MA, Hamdy A. Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson’s disease. *Mov Disord*. 2006;21(12):2201-2205.

12. Mally J, Farkas R, Tothfalusi L, Stone TW. Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson’s disease. *Brain Res Bull*. 2004;64(3):259-263.

13. Pascual-Leone A, Valls-Sole J, Wassermann EM, Hallett M. Benefits and risks of rTMS for treatment of neurological disorders: a meta-analysis. *Pain*. 2001;92(suppl 1):S47-S51.

14. Yang C, Guo Z, Peng H, et al. Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson’s disease: A Meta-analysis. *Brain Behav*. 2018;8(11):e01132.

15. Yokoe M, Mano T, Maruo T, et al. The optimal stimulation site for high-frequency repetitive transcranial magnetic stimulation in Parkinson’s disease: A double-blind crossover pilot study. *J Clin Neurosci*. 2018;47:72-78.

16. Gonzalez-Garcia N, Armony JL, Soto J, Trejo D, Alegría MA, Drucker-Colin R. Effects of rTMS on Parkinson’s disease: a longitudinal fMRI study. *J Neuroimul*. 2011;258(7):1268-1280.

17. Alagona G, Bella R, Ferri R, et al. Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. *Neurosci Lett*. 2001;314(1–2):57-60.

18. Jukunen P, Jauhiainen AM, Westernen-Punnonen S, et al. Navigated TMS combined with EEG in mild cognitive impairment and Alzheimer’s disease: a pilot study. *J Neurosci Methods*. 2008;172(2):270-276.

19. Bentwich J, Dobronevsky E, Aichenbaum S, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer’s disease: a proof of concept study. *J Neural Transm (Vienna)*. 2011;118(3):463-471.

20. Zhao J, Li Z, Cong Y, et al. Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer’s disease patients. *Oncotarget*. 2017;8(20):33864-33871.

21. Nguyen JP, Suarez A, Kemoun G, et al. Repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer’s disease. *Neurophysiol Clin*. 2017;47(1):47-53.

22. Alcala-Lozano R, Morelos-Santana E, Cortes-Sotres JF, Garza-Villarreal EA, Sosa-Ortiz AL, Gonzalez-Olvera JJ. Similar clinical improvement and maintenance after rTMS at 5 Hz using a simple vs. complex protocol in Alzheimer’s disease. *Brain Stimul*. 2018;11(3):625-627.

23. Lee J, Choi BH, Oh E, Sohn EH, Lee AY. Treatment of Alzheimer’s disease with repetitive transcranial magnetic stimulation combined with cognitive training: a prospective, randomized, double-blind, placebo-controlled study. *J Clin Neuro*. 2016;12(1):57-64.

24. Rabey JM, Dobronevsky E, Aichenbaum S, Gonen O, Marton RG, Khagirekht M. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer’s disease: a randomized, double-blind study. *J Neural Transm (Vienna)*. 2013;120(5):813-819.

25. Chou YH, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer’s disease. *Neurobiol Aging*. 2020;86:1-10.

26. Liao X, Li G, Wang A, et al. Repetitive transcranial magnetic stimulation as an alternative therapy for cognitive impairment in Alzheimer’s disease: a meta-analysis. *J Alzheimers Dis*. 2015;48(2):463-472.

27. Zhang N, Xing M, Wang Y, Tao H, Cheng Y. Repetitive transcranial magnetic stimulation enhances spatial learning and synaptic plasticity via the VEGF and BDNF-NMDAR pathways in a rat model of vascular dementia. *Neuroscience*. 2015;311:284-291.

28. Yang HY, Liu Y, Xie JC, Liu NN, Tian X. Effects of repetitive transcranial magnetic stimulation on synaptic plasticity and apoptosis in vascular dementia rats. *Behav Brain Res*. 2015;281:149-155.

29. Zhang XQ, Li L, Hsu JT, Cheng M, Li LH. Effects of repetitive transcranial magnetic stimulation on cognitive function and cholinergic activity in the rat hippocampus after vascular dementia. *Neural Regen Res*. 2018;13(8):1384-1389.

30. Rektorova I, Megova S, Bares M, Rektor I. Cognitive functioning after repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia: a pilot study of seven patients. *J Neurol Sci*. 2005;229:157-161.

31. Sledzkaeva S, Rektorova I, Fanfrolova Z, Rektor I. Neurocognitive effects of repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia. *J Psychophysiol*. 2008;22(1):14-19.

32. Weaver L, Rostain AL, Mace W, Akhtar U, Moss E, O’Reardon JP. Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study. *J ECT*. 2012;28(2):98-103.

33. Alyagon U, Shahar H, Hadar A, et al. Alleviation of ADHD symptoms by non-invasive right prefrontal stimulation is correlated with EEG activity. *Neuroimage Clin*. 2020;26:102206.

34. Paz Y, Friedwald K, Levkovitz Y, et al. Randomised sham-controlled study of high-frequency bilateral deep transcranial magnetic stimulation (dTMS) to treat adult attention hyperactive disorder (ADHD): Negative results. *World J Biol Psychiatry*. 2018;19(7):561-566.

35. Costanzo F, Menghini D, Caltagirone C, Oliveri M, Vicari S. How to improve reading skills in dyslexics: the effect of high frequency rTMS. *Neuropsychologia*. 2013;51(14):2953-2959.

36. Baron-Cohen S, Scott FJ, Allison C, et al. Prevalence of autism-spectrum conditions: UK school-based population study. *Br J Psychiatry*. 2009;194(6):500-509.

37. Braun JM, Kalkbrenner AE, Just AC, et al. Gestational exposure to endocrine-disrupting chemicals and reciprocal social, repetitive, and stereotypic behaviors in 4- and 5-year-old children: the HOME study. *Environ Health Perspect*. 2014;122(5):513-520.

38. Oberman L, Eldaief M, Fecteau S, Iftet-Miller F, Tornos JM, Pascual-Leone A. Abnormal modulation of corticospinal excitability in adults with Asperger’s syndrome. *Eur J Neurosci*. 2012;36(6):2782-2788.

39. Sokhadze EM, El-Baz AS, Tasman A, et al. Neuromodulation integrating rTMS and neurofeedback for the treatment of autism spectrum disorder: an exploratory study. *Appl Psychophysiol Biofeedback*. 2014;39(3–4):237-257.

40. Ameis SH, Blumberger DM, Croarkin PE, et al. Treatment of Executive Function Deficits in autism spectrum disorder with repetitive transcranial magnetic stimulation: A double-blind, sham-controlled, pilot trial. *Brain Stimul*. 2020;13(3):539-547.

41. Barahona-Correa JB, Velosa A, Chinho A, Lopes R, Oliveira-Maia AJ. Repetitive transcranial magnetic stimulation for treatment of autism spectrum disorder: a systematic review and meta-analysis. *Front Integr Neurosci*. 2018;12:27.

42. Khaleghi A, Zarafshan H, Vard SR, Mohammadi MR. Effects of non-invasive neurostimulation on autism spectrum disorder: a systematic review. *Clin Psychopharmacol Neurosci*. 2020;18(4):527-552.

43. Bomono L, Rossetti C. Aspects in perceptual-motor development and sensory-motor intelligence in down syndrome. *Rev Bras Crescimento Desenvolv Hum*. 2010;3:723-734.
44. Robles-Bello MA, Sánchez-Teruel D, Camacho-Conde JA. Variables that predict the potential efficacy of early intervention in reading in Down syndrome. *Psicolog ía Educativa*. 2020;26(2):95-100.

45. Roch M, Florit E, Levorato C. Follow-up study on reading comprehension in Down’s syndrome: the role of reading skills and listening comprehension. *Int J Lang Commun Disord*; 2015;1:12.

46. Battaglia F, Quartarone A, Rizzo V, et al. Early impairment of synaptic plasticity in patients with Down’s syndrome. *Neurobiol Aging*. 2008;29(8):1277-1275.

47. O’Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Noninvasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2018;4:CD008208.

48. Hamid P, Malik BH, Hussain ML. Noninvasive transcranial magnetic stimulation (TMS) in chronic refractory pain: a systematic review. *Cureus*. 2019;11(10):e6019.

49. Galhardoni R, Correia GS, Araújo H, et al. Repetitive transcranial magnetic stimulation in chronic pain: a review of the literature. *Arch Phys Med Rehabil*. 2015;96(4 Suppl):S156-172.

50. Gatzinsky K, Bergh C, Liljegren A, et al. Repetitive transcranial magnetic stimulation of the primary motor cortex in management of chronic neuropathic pain: a systematic review. *Scand J Pain*. 2021;21(1):8-21.

51. Cardenas-Rojas A, Pacheco-Barrios K, Giannoni-Luza S, Rivera-O’Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Noninvasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2018;4:CD008208.

52. Guleyupoglu B, Schestatsky P, Edwards D, Fregni F, Bikson M. *J Lang Commun Disord*; 2015;1:12.

53. Battaglia F, Quartarone A, Rizzo V, et al. Early impairment of synaptic plasticity in patients with Down’s syndrome. *Neurobiol Aging*. 2008;29(8):1277-1275.

54. O’Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Noninvasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2018;4:CD008208.

55. Stagg CJ, Bachtiar V, Amadi U, et al. Local GABA concentration...
82. Finiguerra A, Borgatti R, Urgesi C. Non-invasive brain stimulation for the rehabilitation of children and adolescents with neurodevelopmental disorders: a systematic review. Front Psychol. 2019;10:135.

83. Rios DM, Correia Rios M, Bandeira ID, Queiros Campbell F, de Carvalho VD, Lucena R. Impact of transcranial direct current stimulation on the development of attention and memory in children. Child Neurol Open. 2018;5:2329048X1879825.

84. Lazzaro G, Bertoni S, Menghini D, et al. Beyond reading modulation: temporo-parietal tDCS alters visuo-spatial attention and motion perception in dyslexia. Brain Sci. 2021;11(2):263.

85. Costanzo F, Rossi S, Varuzza C, Varvara P, Vicari S, Menghini D. Long-lasting improvement following tDCS treatment combined with a training for reading in children and adolescents with dyslexia. Neuropsychologia. 2019;130:38-43.

86. Heth I, Lavidor M. Improved reading measures in adults with dyslexia following transcranial direct current stimulation treatment. Neuropsychologia. 2015;70:107-113.

87. Cosmo C, Baptista AF, de Araujo AN, et al. A randomized, double-blind, sham-controlled trial of transcranial direct current stimulation in attention-deficit/hyperactivity disorder. PLoS One. 2015;10(8):e0135371.

88. Cosmo C, DiBiasi M, Lima V, et al. A systematic review of transcranial direct current stimulation effects in attention-deficit/hyperactivity disorder. J Affect Disord. 2020;276:1-13.

89. Dubreuil-Vall L, Gomez-Bernal F, Villegas AC, et al. Transcranial direct current stimulation to the left dorsolateral prefrontal cortex improves cognitive control in patients with attention-deficit/hyperactivity disorder: a randomized behavioral and neurophysiological study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(4):439-448.

90. Salehinajed MA, Nejati V, Mosayebi-Samani M, et al. Transcranial direct current stimulation in ADHD: A systematic review of efficacy, safety, and protocol-induced electrical field modeling results. Neurosci Bull. 2020;36(10):1191-1212.

91. Salehinajed MA, Wischnewski M, Nejati V, Vicario CM, Nitsche MA. Transcranial direct current stimulation in attention-deficit/hyperactivity disorder: A meta-analysis of neuropsychological deficits. PLoS One. 2019;14(4):e0215095.

92. Allenby C, Falcone M, Bernardo L, et al. Transcranial direct current stimulation decreases impulsivity in ADHD. Brain Stimul. 2018;11(5):974-981.

93. Avvichayapat N, Rotenberg A, Gersner R, et al. Transcranial direct current stimulation for treatment of refractory childhood focal epilepsy. Brain Stimul. 2013;6(4):696-700.

94. Faria P, Fregni F, Sebastiao F, Dias AI, Leal A. Feasibility of focal transcranial DC polarization with simultaneous EEG recording: preliminary assessment in healthy subjects and human epilepsy. Epilepsy Behav. 2012;25(3):417-425.

95. Yang D, Wang Q, Xu C, et al. Transcranial direct current stimulation reduces seizure frequency in patients with refractory focal epilepsy: A randomized, double-blind, sham-controlled, and three-arm parallel multicenter study. Brain Stimul. 2020;13(1):109-116.

96. Yook SW, Park SH, Seo JH, Kim SJ, Ko MH. Suppression of seizure by cathodal transcranial direct current stimulation in an epileptic patient - a case report. Ann Rehabil Med. 2011;35(4):579-582.

97. Gschwind M, Seeck M. Transcranial direct-current stimulation as treatment in epilepsy. Expert Rev Neurother. 2016;16(12):1427-1441.

98. Regner GG, Pereira P, Leff TA, et al. Preclinical to clinical translation of studies of transcranial direct-current stimulation in the treatment of epilepsy: a systematic review. Front Neurosci. 2018;12:189.

99. San-Juan D, Morales-Quezada L, Orozco Garduno AJ, et al. Transcranial direct current stimulation in epilepsy. Brain Stimul. 2015;8(3):455-464.

100. Sudbrack-Oliveira P, Barbosa MZ, Thome-Souza S, et al. Transcranial direct current stimulation (tDCS) in the management of epilepsy: A systematic review. Seizure. 2021;86:85-95.

101. Collange Grecco LA, de Almeida Carvalho Duarte N, Mendonça ME, Galli M, Fregni F, Oliveira CS. Effects of anodal transcranial direct current stimulation combined with virtual reality for improving gait in children with spastic diparetic cerebral palsy: a pilot, randomized, controlled, double-blind, clinical trial. Clin Rehabil. 2015;29(12):1212-1223.

102. Gillick B, Menk J, Mueller B, et al. Synergistic effect of combined transcranial direct current stimulation/constraint-induced movement therapy in children and young adults with hemiparesis: study protocol. BMC Pediatr. 2015;15:178.

103. Grecco LA, Duarte Nde A, de Mendonça ME, et al. Effect of transcranial direct current stimulation combined with gait and mobility training on functionality in children with cerebral palsy: study protocol for a double-blind randomized controlled clinical trial. BMC Pediatr. 2013;13:168.

104. Lazzari RD, Politi F, Santos CA, et al. Effect of a single session of transcranial direct-current stimulation combined with virtual reality training on the balance of children with cerebral palsy: a randomized, controlled, double-blind trial. J Phys Ther Sci. 2015;27(3):763-768.

105. Fleming MK, Theologis T, Buckingham R, Johansen-Berg H. Transcranial direct current stimulation for promoting motor function in cerebral palsy: a review. J Neuroeng Rehabil. 2018;15(1):121.

106. Hamilton A, Wakely L, Marquez J. Transcranial direct-current stimulation on motor function in pediatric cerebral palsy: a systematic review. Pediatr Phys Ther. 2018;30(4):291-301.

107. Saleem GT, Crasta JE, Slomine BS, Cantarero GL, Suskauer SJ. Transcranial direct current stimulation in pediatric motor disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2019;100(4):724-738.

108. Antal A, Terney D, Kuhn S, Paulus W. Anodal transcranial direct current stimulation of the motor cortex ameliorates chronic pain and reduces short intracortical inhibition. J Pain Symptom Manage. 2010;39(5):890-903.

109. Pinto CB, Teixeira Costa B, Duarte D, Fregni F. Transcranial direct current stimulation as a therapeutic tool for chronic pain. J ECT. 2018;34(3):e36-e50.

110. De Souza CG, Pegado R, Costa J, et al. Alternate sessions of transcranial direct current stimulation (tDCS) reduce chronic pain in women affected by chikungunya. A randomized clinical trial. Brain Stimul. 2021;14(3):541-548.

111. Ferreira CM, de Carvalho CD, Gomes R, Bonifacio de Assis ED, Andrade SM. Transcranial direct current stimulation and mirror therapy for neuropathic pain after brachial plexus avulsion: a randomized, double-blind, controlled pilot study. Front Neurol. 2020;11:568261.

112. Yeh NC, Yang YR, Huang SF, Ku PH, Wang RY. Effects of transcranial direct current stimulation followed by exercise on neuropathic pain in chronic spinal cord injury: a double-blind randomized controlled pilot trial. Spinal Cord. 2021;59(6):684-692.

113. Conde-Antón Á, Hernando-Garío I, Jiménez-del-Barrio S, Mingo-Gómez MT, Medrano-de-la-Fuente R, Ceballos-Laita L. Efectos de la estimulación transcranial por corriente directa y de la estimulación magnética transcranial en pacientes con fibromialgia. Revisión sistemática. Neurologia. 2020. http://dx.doi.org/10.1016/j.jnrl.2020.07.024

114. De Icco R, Putorti A, De Paoli I, et al. Anodal transcranial direct current stimulation in masticatory muscle disorders: a systematic review and meta-analysis. J ECT. 2020;36(10):1191-1209.

115. Concerto C, Al Sawah M, Chusid E, et al. Anodal transcranial direct current stimulation for chronic pain in the elderly: a pilot study. Aging Clin Exp Res. 2016;28(2):231-237.
116. Bayer KE, Neeb L, Bayer A, Wiese JJ, Siegmund B, Pruss MS. Reduction of intra-abdominal pain through transcranial direct current stimulation: A systematic review. *Medicine (Baltimore).* 2019;98(39):e17017.

117. Piennaar IS, Lee CH, Elson JL, et al. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson’s disease. *Neurobiol Dis.* 2015;74:392-405.

118. Okun MS, Foote KD. Multiple lead method for deep brain stimulation. In: Google Patents. 2012.

119. Chiken S, Nambu A. Mechanism of deep brain stimulation: inhibition, excitation, or disruption? *Neuroscientist.* 2016;22(3):313-322.

120. Lin W, Bao WQ, Ge JJ, et al. Fornix deep brain stimulation in severe Alzheimer’s disease: A case report. *World J Clin Cases.* 2020;8(20):4938-4945.

121. Lozano AM, Fosdick L, Chakravarty MM, et al. A phase II study of fornix deep brain stimulation in mild Alzheimer’s disease. *J Alzheimers Dis.* 2016;54(2):777-787.

122. Leoutsakos JS, Yan H, Anderson WS, et al. Deep brain stimulation targeting the fornix for mild Alzheimer Dementia (the ADvance Trial): A two year follow-up including results of delayed activation. *J Alzheimers Dis.* 2018;64(2):597-606.

123. Liu H, Temel Y, Boonstra J, Hescham S. The effect of fornix deep brain stimulation in brain diseases. *Cell Mol Life Sci.* 2020;77(17):3279-3291.

124. Luo Y, Sun Y, Tian X, et al. Deep brain stimulation for Alzheimer’s disease: stimulation parameters and potential mechanisms of action. *Front Aging Neurosci.* 2021;13:619543.

125. Khan IS, D’Agostino EN, Calnan DR, Lee JE, Aronson JP. Deep brain stimulation for memory modulation: a new frontier. *World Neurosurg.* 2019;126:638-646.

126. Bratsos S, Karponis D, Saleh SN. Efficacy and safety of deep brain stimulation in the treatment of Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. *Cureus.* 2018;10(10):e3474.

127. Mao Z, Ling Z, Pan L, et al. Comparison of efficacy of deep brain stimulation of different targets in parkinson’s disease: a network meta-analysis. *Front Aging Neurosci.* 2019;11:23.

128. Peng L, Fu J, Ming Y, Zeng S, He H, Chen L. The long-term efficacy of STN vs GPi deep brain stimulation for Parkinson’s disease: A meta-analysis. *Medicine (Baltimore).* 2018;97(35):e121153.

129. Vizcarra JA, Situ-Kcomt M, Artusi CA, et al. Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects. *J Neurol.* 2019;266(2):289-297.

130. Flora ED, Perera CL, Cameron AL, Maddern GJ. Deep brain stimulation for essential tremor: a systematic review. *Mov Disord.* 2010;25(11):1550-1559.

131. Giordano M, Caccavella VM, Zaed I, et al. Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: a systematic review and pooled analysis of functional outcomes. *J Neurol Neurosurg Psychiatry.* 2020;91(12):1270-1278.

132. Sturm V, Fricke O, Buhrlé CP, et al. DBS in the basolateral amygdala improves symptoms of autism and related self-injurious behavior: a case report and hypothesis on the pathogenesis of the disorder. *Front Hum Neurosci.* 2012;6:341.

133. Park HR, Kim IH, Kang H, et al. Nucleus accumbens deep brain stimulation for a patient with self-injurious behavior and autism spectrum disorder: functional and structural changes of the brain: report of a case and review of literature. *Acta Neurochir (Wien).* 2017;159(1):137-143.

134. Lim SN, Lee ST, Tsai YT, et al. Electrical stimulation of the anterior nucleus of the thalamus for intractable epilepsy: a long-term follow-up study. *Epilepsia.* 2007;48(2):342-347.

135. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. *Epilepsia.* 2010;51(5):899-908.

136. Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. *Neurology.* 2015;84(10):1017-1025.

137. Sprengers M, Vonck K, Carrette E, Marson AG, Boon P. Deep brain and cortical stimulation for epilepsy. *Cochrane Database Syst Rev.* 2017;7:CD008497.

138. Yan H, Toyota E, Anderson M, et al. A systematic review of deep brain stimulation for the treatment of drug-resistant epilepsy in childhood. *J Neurosurg Pediatr.* 2018;23(3):274-284.

139. Zhou JJ, Chen T, Farber SH, Shetter AG, Ponce FA. Open-loop deep brain stimulation for the treatment of epilepsy: a systematic review of clinical outcomes over the past decade (2008-present). *Neurosur Focus.* 2018;45(2):E5.

140. Frizon LA, Yamamoto EA, Nagel SJ, Simonson MT, Hogue O, Machado AG. Deep brain stimulation for pain in the modern era: a systematic review. *Neurosurgery.* 2020;86(2):191-202.

141. Galafassi GZ, Pires S, de Aguiar PH, et al. Neuromodulation for medically refractory neuropathic pain: spinal cord stimulation, deep brain stimulation, motor cortex stimulation, and posterior insula stimulation. *World Neurosurg.* 2021;146:246-260.

142. Abreu V, Vaz R, Rebelo V, et al. Thalamic deep brain stimulation for neuropathic pain: efficacy at three years’ follow-up. *Neuromodulation.* 2017;20(5):504-513.

143. Levi V, Cordella R, D’Ammando A, et al. Dorsal anterior cingulate cortex (ACC) deep brain stimulation (DBS): a promising surgical option for the treatment of refractory thalamic pain syndrome (TPS). *Acta Neurochir (Wien).* 2019;161(8):1579-1588.

144. Boccard SGJ, Prangnell SJ, Pycroft L, et al. Long-term results of deep brain stimulation of the anterior cingulate cortex for neuro-pathic pain. *World Neurosurg.* 2017;106:625-637.

145. Coulombe MA, Elkaim LM, Alothabi NM, et al. Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. *J Neurosurg Pediatr.* 2018;23(2):236-246.

146. Schroick LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. *Mov Disord.* 2015;30(4):448-471.

147. Balderrmann JC, Schuller T, Huys D, et al. Deep brain stimulation for tourette-syndrome: a systematic review and meta-analysis. *Brain Stimul.* 2016;9(2):296-304.

148. Servello D, Zekaj E, Saleh C, Zanaboni Dina C, Porta M. Sixteen years of deep brain stimulation in Tourette’s Syndrome: a critical review. *J Neurosurg Sci.* 2016;60(2):218-229.

149. Xu W, Zhang C, Deeb W, et al. Deep brain stimulation for Tourette’s syndrome. *Transl Neurodegener.* 2020;9:4.

150. Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-analysis of ten years’ experience. *Mov Disord.* 2007;22(12):1722-1728.